Why the study?
Does 3,5-diiodothyropropionic acid (DITPA) improve hemodynamic and lipid parameters in patients with moderately severe congestive heart failure?
Population
19 patients with moderately severe congestive heart failure
Comparison
3,5-diiodothyropropionic acid (DITPA) for 4 weeks vs Placebo
Design
RCT, randomized, double-blind
Follow-up
4 weeks
Authors
Loading...
DITPA improves short-term hemodynamics in HF; extends thyroid analog data but requires larger outcome trials.
Does 3,5-diiodothyropropionic acid (DITPA) improve hemodynamic and lipid parameters in patients with moderately severe congestive heart failure?
DITPA, a thyroid hormone analog, improved cardiac index and diastolic function while lowering lipids in a pilot study of heart failure patients.
Morkin et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: